"AI doesn't know your market. It doesn't know why Italy is behind and Spain is ahead. We do."
One integrated diagnostic. Four lenses. One story. We help pharma commercial teams turn fragmented sales, field, access, and account signals into a defensible answer on whether a launch is on track — and where to focus next.
Launch & Post-LaunchÂ
Diagnostic Intelligence
Business Consulting · Launch & Brand Strategy
Trusted by commercial teams launching in specialty therapy areas across the EU
01 · The moment this is built for
02 · What we deliver
03 · How we get there
04 · Proof, from the field
05 · Is this relevant to your team?
TODAY
01
Sales, field, access, invoice, and account data sit in different systems, owned by different teams. Every QBR is a debate about whose numbers are right.
Fragmented
03
One defensible diagnostic
Leadership walks in with one agreed answer on where momentum is concentrated, what's holding it back, and where to invest next.
OUTCOME
phamax BRINGS
02
Connected & AI-ready
Domain experts harmonise, govern, and reconcile the foundation — pharma-fluent from day one, built to be trusted before it reaches a leadership screen.
01 · The moment this is built for
Every launch reaches
the point whereÂ
leadership asks
the hard question.
The product is live. The data exists — sales, field, access, invoice, account signals, owned by a dozen different teams. But nobody can give a clean answer on whether the launch is on track, or what to do next. That's the moment this diagnostic is built for.
02 · What we deliver
One integrated diagnostic. Â
Four lenses. One story.
This is not a dashboard project and not a list of decision packs. It is a single diagnostic that examines a launch through four lenses commercial leadership already cares about — each designed to answer a question the team is already asking.
Same data the client already has. New foundation. New diagnostic. New conversation with leadership.
Four lenses.
One story.
Patient coverage
Commercial performance
Competitive position
Sales attainment
Before every leadership meeting,
the team needs to answer one question quickly and consistently: is the launch on track? The diagnostic puts the full commercial picture in one view, from one reconciled source.
National numbers flatten the story.
A strong quarter in one region can mask underperformance in three others.
The diagnostic breaks the market down geographically — a map, not a national average.
The question is rarely whether
a competitor has an advantage. It's where, by how much, and whether the gap is closing or widening. External market data sits alongside internal sales.
Knowing where patients are — and whether the field has actually reached them — is the difference betweenÂ
a coverage strategy and a guess.
Lens 01
Lens 02
Lens 03
Lens 04
Connect
01
Build the foundation
Fragmented commercial, market, sales and field inputs harmonised into one decision-ready intelligence layer — pharma-fluent and governed.
03
Recommend the next move
Performance signals translated into territory-level recommendations — defensible decisions for the next phase of growth.
Decide
Examine
02
Apply the diagnostic
The launch examined through four targeted diagnostic lenses, each designed to answer
a specific question leadership is already asking.
03 · How we get there
Connect. Examine. Decide.
A three-step approach that turns fragmented commercial signals into defensible decisions for the next phase of growth.
Challenge
A global oncology company was over a year into a German rare disease launch, competing against an established incumbent. Performance data existed in volume but sat across teams, formats, and reporting layers. One question defined the next planning cycle:Â where was the launch gaining traction, and where did resources need to be redirected?
04 · Proof, from the field
Unlocking full market potential throughÂ
post-launch signals.
Rare Disease · Oncology · Germany
Approach
phamax built a decision-ready intelligence layer — connecting commercial, market, sales, and field inputs into one governed foundation. A diagnostic framework was then applied across four lenses: commercial performance, sales attainment, competitive position, and patient opportunity & field coverage.
Outcome
Pre-meeting reconciliation disappeared. Leadership reviewed performance from one shared foundation — and the conversation shifted from "whose numbers are right?" to "what should we do next?" Regional decision-making replaced national averages. Field deployment was tied to patient opportunity, not assumption.
Example diagnostic output — post-launch signals consolidated into one commercial decision view. Anonymised.
1
Decision-ready foundation, ready for AI-enabled analytics next
4
Diagnostic lenses across performance, competition and field priorities
200+
Brick-level regions analysed
across Germany
Leadership review or brand planning is coming up, and the team needs a defensible narrative.
04
Sales, field, access, and account data sit in separate systems.
03
Uptake is uneven across markets, regions, or accounts.
02
A specialty product has launched in the last 6–24 months.
01
05 · Is this relevant to your team?
The diagnostic is most useful when this sounds familiar.
If any of this reflects the questions your team is currently trying to answer, we should talk.